Rivercell
A Paris startup combining an automated wet lab, proprietary single-cell data and an AI virtual-cell model.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Rivercell, Netsec, MintNeuro — $25M for virtual cells, over $10M for cybersecurity and $5M for neural chips — Daily News October 7, 2026
Listen to the episodeAbout Rivercell
Started in 2025 by Yann Fleureau and joined in 2026 by Eric Durand, Rivercell is building a proprietary platform to generate multimodal, time-resolved biological data and train an AI model of the cell. On October 7, 2026, it announced a $25 million seed round led by HV, with HCVC, Alven and Bpifrance Digital Venture.
The Story
Yann Fleureau started Rivercell after Cardiologs; Eric Durand brought oncology data-science experience from Novartis, Owkin and Bioptimus.
How Rivercell works
Business Model
A B2B research platform for pharmaceutical and biotechnology companies, with potential data and model access or licensing.
Revenue Model
Undisclosed; the final commercial model and customers are not public.
Products & Services
Key Products
- AI Virtual Cell
- Proprietary biological data-generation platform
Core Use Cases
- Predicting cellular responses to drugs
- Simulating genetic changes
- Generating multimodal single-cell data
- Supporting drug discovery
Market & Clients
Key Customers
Pharmaceutical companies, biotechs and research groups; named customers are undisclosed.
Geographic Presence
How Rivercell competes
Competitive Advantages
- Control of both data generation and modelling
- Interventional, time-resolved data
- Proprietary automated wet lab
How Rivercell grows
Growth Strategy
Expand the Paris wet lab, scale the data-generation platform and launch the AI Virtual Cell programme.
Distribution Model
Direct collaborations with pharmaceutical, biotech and research organisations; commercial terms are undisclosed.
Moat (Defensibility)
Proprietary biological datasets, experimental infrastructure and integration between wet lab and AI models.
Regulatory Context
Use in therapeutic programmes will require scientific validation and compliance with rules governing biological data, research and drug development.
Key Risks
- Predictions that do not generalise to new biological contexts
- High laboratory and compute costs
- Long scientific-validation timelines
- No demonstrated clinical or drug-programme outcomes
Strategic Insights
- Integrating the lab and AI may create an advantage if it produces hard-to-replicate data.
- Value depends on out-of-distribution predictive performance and usefulness in real drug programmes.
Funding & Investors
Total Funding
Funding Rounds
- 2026 - : $25M
Lead: HV
Key Investors
Founding Team
Founders
Key Metrics
Lessons from Rivercell
- In vertical models, building the data engine may be more defensible than the software layer alone.
- Claims about reducing physical experiments require prospective validation.
Similar Startups
Alan
Health insurer founded in Paris in 2016 and valued by the company at €5.5B on 2 September 2026. It raised €631M of primary capital to 2024, plus 2026 rounds of mixed type.
Read AnalysisLucis
Paris-based preventive healthcare startup analysing 110+ biomarkers and using clinically reviewed AI to guide personalised prevention.
Read AnalysisBiolevate
Paris startup, AI platform with source-linked outputs for pharma and biotech companies. €30M Series A in 2026.
Read Analysis